InterCure Advances towards NASDAQ Listing Exchange Expected to Begin in Last Week of July

TORONTO, July 19, 2021 (GLOBE NEWSWIRE) – InterCure Ltd. (TSX: INCR.U, TASE: INCR) (dba Canndoc) (“Company”) Happy to further disclose that regarding its confidential filing with the United States Securities and Exchange Commission (“Security and Exchange Commission”)SECONDS“) In its 20F registration statement on April 20, 2021, it filed a 20F registration statement under the Securities Exchange Act of 1933 and an F-1 registration statement under the Securities Act of 1933. The full report is available on the Company’s SEDAR file as well as on EDGAR:

20-F: https://www.sec.gov/Archives/edgar/data/0001857030/000149315221016836/form20fr12b.htm

F-1: https://www.sec.gov/Archives/edgar/data/0001857030/000149315221016926/formdrsf-1.htm

Listing on NASDAQ must meet all applicable listing and regulatory requirements, including registration of Common Stocks with SEC, NASDAQ requirements and approvals. Upon receipt of all necessary approvals, the Company will issue a press release announcing its first day of trading on NASDAQ.

Introduction to InterCure (dba Canndoc)

InterCure (dba Canndoc) (TSX: INCR.U, TASE: INCR) is Israel’s leading, fastest growing and most profitable cannabis company. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer certified medical cannabis products. fine (GMP) and pharmaceuticals. InterCure leverages its market-leading distribution network, best-in-class international partners and highly profitable vertically integrated “seeds for sale” model to become a profitable cannabis company highest profits globally outside of North America.

InterCure is listed on the Toronto Stock Exchange under the symbol INCR.U and traded on the Tel Aviv Stock Exchange under the symbol INCR.TA. Subject to the fulfillment of NASDAQ listing conditions, InterCure common stock is expected to begin trading on NASDAQ during the last week of July 2021 and will trade under the symbol “INCR.” .

For more information, visit: http://www.intercure.co

Forward-looking statement

This press release may contain forward-looking information within the meaning of applicable securities laws, reflecting InterCure’s current expectations of future events. The words “will,” “expect,” “intend,” “plan,” and similar expressions are often intended to identify forward-looking information, although not all forward-looking information. all contain these identifiers. Specific forward-looking information in this press release includes, but is not limited to: the listing of Common Stock on NASDAQ. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which may result in fact differs materially from what is disclosed or implied by such. forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions. InterCure is under no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, unless expressly required by applicable law.

Contact:

InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@canndoc-pharma.com
(972) 77-460-5012

Main logo

https://financialpost.com/globe-newswire/intercure-advances-towards-nasdaq-listing-trading-expected-to-begin-in-the-last-week-of-july | InterCure Advances towards NASDAQ Listing Exchange Expected to Begin in Last Week of July

Apkdownload

Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@interreviewed.com. The content will be deleted within 24 hours.

Related Articles

Back to top button